Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2275b2ad844d287

Jump to content

Bupropion/zonisamide

From Wikipedia, the free encyclopedia
(Redirected from Empatic)
Bupropion/zonisamide
Combination of
BupropionNorepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
ZonisamideSulfonamide anticonvulsant
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
  (verify)

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]

See also

[edit]

References

[edit]
  1. 1 2 3 "Bupropion/Zonisamide - AdisInsight".
  2. ↑ "Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half". Archived from the original on 2010-01-11. Retrieved 2010-01-07.
  3. ↑ "Empatic Obesity Drug Information and News". Archived from the original on 2017-07-02. Retrieved 2010-01-07.
  4. ↑ Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
  5. ↑ Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Bupropion/zonisamide&oldid=1330774690"